Nicholas Tadros, MD
Urology · Columbus, OHNPI 1114185394
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (39.4%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 86.5% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2023 at $11,469 and has fallen 99.0% since, to $118 in 2025. Among urology clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 256 payments — averaging $126.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$28K
- Valencia Technologies Corporation$1K
- Neotract Inc.$1K
- Olympus America Inc.$608
- Astellas Pharma US Inc$474
- Urogen Pharma, Inc.$144
- plus $1K from 13 others
Across 26 payments — averaging $2989.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$70K
- C. R. Bard, Inc. & Subsidiaries$8K
What the payments were for
- Consulting fees$4,90015%
- Speaking & faculty fees$12,70039%
- Travel & lodging$7,42823%
- Food & beverage$7,04522%
- Education$1881%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 190 | $27,908 |
| Valencia Technologies Corporation | 7 | $1,102 |
| Neotract Inc. | 7 | $1,015 |
| Olympus America Inc. | 16 | $608 |
| Astellas Pharma US Inc | 16 | $474 |
| Urogen Pharma, Inc. | 1 | $144 |
| Cook Medical LLC | 2 | $134 |
| Endo Pharmaceuticals Inc. | 1 | $125 |
| Teleflex LLC | 3 | $124 |
| Medtronic | 1 | $119 |
| Antares Pharma, Inc. | 3 | $111 |
| Ambu Inc. | 1 | $92 |
| Tolmar Pharmaceuticals, Inc. | 1 | $87 |
| Johnson & Johnson | 1 | $82 |
| Coloplast | 2 | $54 |
| Convatec Inc. | 1 | $31 |
| Halozyme Inc | 1 | $22 |
| KARL Storz Endoscopy-america | 1 | $15 |
| Axonics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMS$6,204
- REZUM$5,745
- GENERAL - THERAPIES$2,293
- AMS 700 CXR RTE KIT$1,229
- UroLift$960
- eCoin Device Kit$851
- GENERAL BPH$586
- iTIND System$278
- GENERAL ERECTILE DYSFUNCTION$252
- JELMYTO$144
- Tria Firm$134
- XIAFLEX$125
- Cook Medical Stents$120
- INTERSTIM$119
- GENERAL KIDNEY STONE DISEASE$105
How this compares
$32,261 in reported general payments places this provider in the 90th percentile of 485 urology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 129 | $87,405 |
| GemtesaVibegron | 40 | $24,945 |
| Testosterone | 24 | $5,555 |
| Solifenacin Succinate | 23 | $3,614 |
| Tamsulosin Hcl | 245 | $3,273 |
| Silodosin | 21 | $2,202 |
| Testosterone Cypionate | 62 | $2,060 |
| Finasteride | 75 | $636 |
| Oxybutynin Chloride ErOxybutynin Chloride | 26 | $476 |
| Cabergoline | 11 | $406 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 15 | $336 |
| NitrofurantoinNitrofurantoin Macrocrystal | 11 | $280 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 34 | $94 |
| Oxycodone Hcl | 20 | $84 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 14 | $65 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $474 | $87,405129 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 485 urology providers in Ohio.
Other urology in Columbus
- Bodo KnudsenColumbus$108K
- Gregory LoweColumbus$106K
- George HoColumbus$72K
- Hiren PatelColumbus$54K
- Michael FarrellColumbus$52K
- Eric RiedingerColumbus$27K
- Eric SingerColumbus$25K
- Cheryl LeeColumbus$22K
- Matthew LeeColumbus$16K
- Lawrence GervasiMiddleburg Heights$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.